The findings suggested that JWHLGJD is effective against CRA through a variety of pathways, including pathways in cancer, lipid and atherosclerosis, PI3K-Akt signaling pathway, MAPK signaling pathway and microRNAs in cancer. The gene discussed is AKT1; the disease is atherosclerosis.